Mutant p53 Exploits Enhancers to Elevate Immunosuppressive Chemokine Expression and Impair Immune Checkpoint Inhibitors in Pancreatic Cancer.

Autor: Mahat DB; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Kumra H; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA., Castro SA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Metcalf E; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Nguyen K; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Morisue R; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA., Ho WW; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA., Chen I; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA., Sullivan B; Ragon Institute of Mass General, MIT, and Harvard, MA, 02139, USA., Yim LK; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Singh A; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Fu J; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Waterton SK; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Cheng YC; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Roberge S; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA., Moiso E; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Chauhan VP; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Silva HM; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA,02139, USA.; Ragon Institute of Mass General, MIT, and Harvard, MA, 02139, USA.; Howard Hughes Medical Institute, Cambridge, MA, 02139, USA., Spranger S; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA,02139, USA.; Ragon Institute of Mass General, MIT, and Harvard, MA, 02139, USA., Jain RK; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA., Sharp PA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA,02139, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Aug 30. Date of Electronic Publication: 2024 Aug 30.

Aspirin for pre-eclampsia: beware of subgroup meta-analysis.

Autor: Meher, S.^1,2, Alfirevic, Z.¹

Publikováno v: Ultrasound in Obstetrics & Gynecology. May2013, Vol. 41 Issue 5, p479-485. 7p.

Wnt inhibition alleviates resistance to immune checkpoint blockade in glioblastoma.

Autor: Jain R; MGH., Krishnan S; MGH., Lee S; MGH., Amoozgar Z; MGH., Subudhi S; Massachusetts General Hospital., Kumar A; MGH., Posada J; MGH., Lindeman N; Brigham and Women's Hospital., Lei P; MGH., Duquette M; MGH., Roberge S; MGH., Huang P; MGH., Andersson P; MGH., Datta M; MGH., Munn L; MGH., Fukumura D; Massachusetts General Hospital.

Publikováno v: Research square [Res Sq] 2023 Dec 26. Date of Electronic Publication: 2023 Dec 26.

Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis.

Autor: Ghesquiere L; Reproduction, Mother and Child Health Unit, Research Center of the Centre Hospitalier Universitaire de Québec - Université Laval, Québec, Canada (Dr Ghesquiere, Ms Marchant, Ms Foisy, and Drs Roberge and Bujold); Department of Obstetrics, Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France (Dr Ghesquiere)., Guerby P; Department of Obstetrics, Hospital Paule De Viguier, Centre Hospitalier Universitaire de Toulouse, Toulouse, France (Dr Guerby)., Marchant I; Reproduction, Mother and Child Health Unit, Research Center of the Centre Hospitalier Universitaire de Québec - Université Laval, Québec, Canada (Dr Ghesquiere, Ms Marchant, Ms Foisy, and Drs Roberge and Bujold)., Kumar N; Department of Obstetrics and Gynecology, King George's Medical University, Lucknow, India (Dr Kumar)., Zare M; Maternal-fetal medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran (Dr Zare)., Foisy MA; Reproduction, Mother and Child Health Unit, Research Center of the Centre Hospitalier Universitaire de Québec - Université Laval, Québec, Canada (Dr Ghesquiere, Ms Marchant, Ms Foisy, and Drs Roberge and Bujold)., Roberge S; Reproduction, Mother and Child Health Unit, Research Center of the Centre Hospitalier Universitaire de Québec - Université Laval, Québec, Canada (Dr Ghesquiere, Ms Marchant, Ms Foisy, and Drs Roberge and Bujold)., Bujold E; Reproduction, Mother and Child Health Unit, Research Center of the Centre Hospitalier Universitaire de Québec - Université Laval, Québec, Canada (Dr Ghesquiere, Ms Marchant, Ms Foisy, and Drs Roberge and Bujold); Department of Obstetrics, Gynecology and Reproduction, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Canada (Dr Bujold). Electronic address: emmanuel.bujold@crchudequebec.ulaval.ca.

Publikováno v: American journal of obstetrics & gynecology MFM [Am J Obstet Gynecol MFM] 2023 Jul; Vol. 5 (7), pp. 101000. Date of Electronic Publication: 2023 May 04.

Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.

Autor: Datta M; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114., Chatterjee S; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114., Perez EM; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.; Broad Institute of MIT and Harvard, Cambridge, MA 02142.; Department of Systems Biology, Harvard Medical School, Boston, MA 02115., Gritsch S; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.; Broad Institute of MIT and Harvard, Cambridge, MA 02142., Roberge S; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114., Duquette M; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114., Chen IX; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114., Naxerova K; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114., Kumar AS; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.; Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02142., Ghosh M; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114., Emblem KE; Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, 0372 Norway., Ng MR; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114., Ho WW; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142., Kumar P; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114., Krishnan S; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114., Dong X; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114., Speranza MC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.; Department of Medicine, Harvard Medical School, Boston, MA 02115., Neagu MR; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA., Iorgulescu JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115., Huang RY; Department of Radiology, Brigham and Women's Hospital, Boston, MA 02115., Youssef G; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215., Reardon DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.; Department of Medicine, Harvard Medical School, Boston, MA 02115., Sharpe AH; Broad Institute of MIT and Harvard, Cambridge, MA 02142.; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA., Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.; Department of Medicine, Harvard Medical School, Boston, MA 02115., Suvà ML; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.; Broad Institute of MIT and Harvard, Cambridge, MA 02142., Xu L; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114., Jain RK; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2023 Feb 07; Vol. 120 (6), pp. e2219199120. Date of Electronic Publication: 2023 Feb 01.